Showing results (21-30 of 51) with videos related to
Sort By:
Pageof 6
Therapeutic Advances in Neurological Disorders|May 5, 2021
Switch from intravenous to subcutaneous immunoglobulin IgPro20 in CIDP patients: a prospective observational study under real-world conditionsStefan Gingele, Moritz Koch, Anna Christina Saparilla, et al.Journal of Neurology|September 3, 2025
The impact of autoimmune comorbidities on multiple sclerosis progression: insights from a longitudinal single-center studyDerya Aslan, Sabrina Bourabia, Bernd Kowall, et al.Journal of Neurology, Neurosurgery, and Psychiatry|January 20, 2026
Discontinuation of ocrelizumab in multiple sclerosis: reoccurrence of disease activityFranz Felix Konen, Franziska Axhausen, Stephanie Wolff, et al.Cells|July 27, 2022
Stem Cell Therapy in Neuroimmunological Diseases and Its Potential Neuroimmunological ComplicationsFranz Felix Konen, Philipp Schwenkenbecher, Konstantin Fritz Jendretzky, et al.Journal of Neurology|April 24, 2025
Added value of optic nerve lesions for multiple sclerosis diagnostic criteriaNima Mahmoudi, Julius Renne, Franz Felix Konen, et al.Frontiers in Neurology|May 4, 2026
Assessing the value of oligoclonal band count in multiple sclerosis: insights from a large cohort analysisKonstantin F Jendretzky, Ulrich Wurster, Franz Felix Konen, et al.Neurology and Therapy|November 19, 2025
Switch from Intravenous to Subcutaneous Immunoglobulin in CIDP and MMN: 12 Months Results from an Observational StudyStefan Gingele, Anna Christina Saparilla Pietschmann, Konstantin F Jendretzky, et al.European Journal of Neurology|January 23, 2026
Does Interrater Variation Influence the Classification According to the Diagnostic Criteria for Multiple Sclerosis?Nima Mahmoudi, Julius Renne, Franz Felix Konen, et al.Cells|January 2, 2019
Ocrelizumab Depletes CD20⁺ T Cells in Multiple Sclerosis PatientsStefan Gingele, Thais Langer Jacobus, Franz Felix Konen, et al.Multiple Sclerosis and Related Disorders|September 19, 2024
Rapid depletion of CD20<sup>+</sup> B and T cells following ofatumumab therapy onsetFranz Felix Konen, Stefan Gingele, Martin W Hümmert, et al.Pageof 6